25I-NBMD
# 25I-NBMD

25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the $5HT_{2A}$ receptor with a Ki of 0.049 nM at the human $5HT_{2A}$ receptor. The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the $5-HT_{2A}$ receptor.

## Legality

### Sweden

The Riksdag added 25I-NBMD to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of January 16, 2015, published by Medical Products Agency (MPA) in regulation LVFS 2014:11 listed as 25I-NBMD, and 2-(4-jodo-2,5-dimetoxifenyl)-N-[(2,3-metylendioxifenyl)metyl]etanamin.

### United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.

## Analogues and derivatives

Analogues and derivatives of 2C-I:

25I-NB*:

* 25I-NBF
* 25I-NBMD
* 25I-NB34MD
* 25I-NBOH
* 25I-NBOMe (NBOMe-2CI)
* 25I-NB3OMe
* 25I-NB4OMe

N-(2C)-fentanyl:

* N-(2C-I) fentanyl
